Back to search results

Phase 2 Study of GX-03 for Moderate to Severe Eczema

This study is testing an experimental topical ointment called GX-03 for adults with moderate to severe atopic dermatitis (eczema). Researchers want to see if GX-03 is effective and safe compared to a "vehicle" (an ointment without the active ingredient). You might be eligible if you are an adult between 18 and 80 years old and have visible eczema. The main goal is to see how much your eczema improves after 8 weeks of treatment, as assessed by a doctor. The study plans to enroll about 110 participants, but the current recruitment status is unclear.

Study design
This is a Phase 2, randomized, double-blind, vehicle-controlled study involving up to 120 participants. Participants will be randomly assigned to receive either GX-03 or a control ointment.
What's involved
You would apply the study treatment to affected areas at least twice daily for 8 consecutive weeks. You would have efficacy evaluations at the start, Week 4, and Week 8, along with weekly safety check-ins.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 8, which suggests follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07355075

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Recruiting
PHASE2Ages 18–80InterventionalTreatment
Turn Therapeutics
~110 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:GX-03Vehicle

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Investigator Global Assessment (IGA) at Week 8
Measured over At Day 56 (Week 8)

Conditions

Eczema Atopic Dermatitis
Eczema
Atopic Dermatitis

Explore related trials

Atopic Dermatitis

Where it's being run

1 sites across 1 states
Texas1

Who to contact

Barry Reece, MS
[email protected]
9728714371
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Pregnant, breastfeeding, or planning pregnancy during the study
Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments
Use of systemic or topical immunosuppressive therapies, including corticosteroids, within 3 weeks prior to enrollment
Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted
Use of topical medications at the test sites within 72 hours prior to enrollment
Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations
Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity

What this trial measures

  • Change in Investigator Global Assessment (IGA) at Week 8At Day 56 (Week 8)

    vIGA-AD score of 0 (clear) or 1 (almost clear) with a ≥2-grade improvement from baseline at Week 8